Analysis by flow cytometry showed binding of the αEpCAM–αCD3 and αEpCAM–αCD28 BiMAb to EpCAM-positive MCF-7 breast cancer cells, whereas irrelevant FAP-specific BiMAb did not bind, as this antigen was not expressed on MCF-7 cells (Figures 1C, 4B). Here, EPCAM is linked to breast cancer.